MedPath

Tagged News

University of Arizona Researchers Identify Drug Candidate That Reverses Heart Failure Progression in Mouse Models

Drug Discovery
  • Researchers at the University of Arizona's Sarver Heart Center have identified a potential drug candidate that may reverse the progression of a challenging form of heart failure in mouse models.
  • The study, published in Cell Metabolism, focused on addressing a specific type of heart failure known for its limited treatment options and high medical burden.
  • While the findings are preliminary and based on animal studies, they highlight potential avenues for future clinical research aimed at improving outcomes for patients with similar cardiac challenges.
  • The research marks a significant step toward expanding therapeutic possibilities for individuals affected by this difficult-to-treat condition.

IonQ Achieves 20-Fold Speedup in Drug Discovery Simulations Through Quantum-Classical Hybrid Computing

Drug Discovery
  • IonQ, AstraZeneca, AWS, and NVIDIA demonstrated a quantum-accelerated drug discovery workflow that achieved over 20-fold improvement in simulation time for the Suzuki-Miyaura reaction, a key pharmaceutical synthesis method.
  • The hybrid system integrated IonQ's Forte quantum processor with NVIDIA CUDA-Q and AWS infrastructure, reducing computational runtime from months to days while maintaining scientific accuracy.
  • This breakthrough represents the most complex chemical simulation run on IonQ hardware to date and demonstrates practical quantum computing applications in pharmaceutical research and development.
  • The collaboration showcases how quantum-enhanced workflows can overcome computational bottlenecks in early-stage drug development, potentially accelerating the multi-year, multi-billion-dollar drug discovery process.

Researchers Identify Two Drug Candidates for Ultra-Rare X-Linked Myopathy Using Zebrafish Model

Rare DiseaseDrug Discovery
  • Researchers have identified two potential drug candidates for treating X-linked myopathy with excessive autophagy (XMEA), an ultra-rare genetic disease documented in only 33 cases globally as of March 2024.
  • The study utilized zebrafish as a model organism to investigate XMEA, which is caused by mutations in the VMA21 gene and leads to progressive muscle weakness affecting the liver and heart.
  • The identified compounds showed promise in mitigating XMEA-related muscle degeneration, representing a significant step forward for a condition that currently lacks effective treatment options.
  • Further testing will be required to confirm the efficacy and safety of these drug candidates before potential clinical application in humans.

India's ₹5,000 Crore PRIP Scheme Signals Major Shift from Generic Manufacturing to Innovation-Led Pharma Growth

Drug Discovery
  • India launches the ₹5,000 crore Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, expected to attract ₹17,000 crore in additional R&D investment by end of 2025.
  • The initiative comes as 24 mega-selling drugs worth over $250 billion in combined annual sales will lose patent protection by 2030, creating unprecedented opportunities for Indian generic manufacturers.
  • Indian pharmaceutical companies including Zydus, Sun Pharma, and Bharat Serums are investing heavily in world-class R&D centers to develop new chemical entities and transition from generic-focused to innovation-driven operations.
  • The sector has grown dramatically from $8 billion in 2005-06 to $50 billion in 2023-24, with India now ranking as the world's third largest pharmaceutical producer by volume.

MIT and Recursion Release Boltz-2: Open-Source AI Model Achieves 1000x Speed Boost in Drug Discovery Screening

AIDrug Discovery
  • MIT and Recursion have released Boltz-2, the first open-source biomolecular co-folding model that jointly predicts 3D complex structures and molecular binding affinity with unprecedented speed and precision.
  • The AI model approaches the accuracy of free energy perturbation (FEP), a gold-standard physics-based method, while performing up to 1,000 times faster, significantly reducing cost and time for large-scale molecular screening.
  • Boltz-2 outperformed all CASP16 affinity challenge participants and is released under the permissive MIT license, making the model, weights, and training pipeline available for both academic and commercial use.
  • The model was trained using Recursion's NVIDIA-powered supercomputer BioHive-2 and incorporates molecular dynamics simulations and approximately 5 million binding affinity measurements.

ImmunoPrecise Achieves AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

AIDrug Discovery
  • ImmunoPrecise Antibodies has identified a highly conserved epitope across all four dengue virus serotypes using its proprietary LENSai™ platform powered by patented HYFT® technology.
  • The discovery represents a major milestone toward developing a universal dengue vaccine by targeting a viral component that remains unchanged despite mutations across all dengue serotypes.
  • The company plans to extend its AI-driven vaccine design platform to other infectious diseases including HIV, Norovirus, and RSV, with early assessments underway for oncology applications.
  • The breakthrough was achieved entirely through computational methods, demonstrating the platform's ability to translate complex biological data into actionable vaccine design without laboratory-based inputs.

Juvenescence Acquires AI Drug Discovery Company Ro5 to Accelerate Age-Related Disease Pipeline

AIDrug Discovery
  • Juvenescence Limited has acquired Ro5 Inc., an AI drug discovery company with a proprietary Biomedical Knowledge Graph comprising over 85 million nodes and 400 million relationships.
  • The acquisition enhances Juvenescence's AI-enabled drug discovery capabilities and supports its strategic partnership with Abu Dhabi-based healthcare company M42.
  • The deal follows a $76 million Series B-1 financing round led by M42, with proceeds supporting clinical milestones across Juvenescence's pipeline targeting age-related diseases in cognition, cardio-metabolism, immunity, and cellular repair.

Elucidata and Sapien Biosciences Form Strategic Partnership to Transform India's Largest Biobank into AI-Ready Data Platform

AIPrecision MedicineDrug Discovery
  • Elucidata and Sapien Biosciences announced a strategic partnership to convert Sapien's 300,000+ patient sample biobank into AI-ready, multimodal data products for drug discovery and diagnostic development.
  • The collaboration will focus initially on building AI models that infer genomic and transcriptomic insights from digital pathology images using NGS-annotated slides from Sapien's cancer biobank.
  • Sapien operates one of the top 10 biobanks globally with over 85,000 cancer patients and represents the largest integrated resource for Asian patient data across multiple disease areas.
  • The partnership aims to address underrepresentation in global omics datasets while accelerating precision medicine through synthetic clinicogenomic data generation.

Aitia Partners with Gustave Roussy to Develop AI-Powered Digital Twins for Cancer Research

AIDrug Discovery
  • Aitia and Gustave Roussy announced a collaboration to transform extensive cancer patient data into "Gemini Digital Twins" - computer-based models that reveal the underlying biological causes of cancer to drive new therapeutic discoveries.
  • The partnership targets cancers with high unmet medical needs, including brain, pancreatic, and ovarian cancers, using Aitia's causal AI engine REFS to analyze multiomic and patient outcome data.
  • Gustave Roussy, Europe's premier cancer research institute treating nearly 50,000 patients annually, will provide de-identified patient data to support the development of next-generation cancer treatments.
  • The collaboration aims to identify specific cancer-causing biological changes to create rational drug targets and optimize clinical trial patient populations across multiple cancer types.

Molecular Health and Axxam Form Strategic Partnership to Accelerate AI-Driven Drug Target Discovery

AIDrug Discovery
  • Axxam S.p.A. and Molecular Health GmbH announced a strategic collaboration to accelerate identification and validation of novel therapeutic targets across multiple therapeutic areas.
  • The partnership integrates Molecular Health's AI-driven Dataome platform with Axxam's DiscoveryMAXX process, combining computational insights with biological validation using advanced in-vitro technologies.
  • The collaboration aims to bridge AI-powered clinical-molecular predictions with rigorous experimental validation to deliver more accurate and efficient early drug discovery solutions to pharmaceutical companies.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.